Jim Simons Landos Biopharma, Inc. Transaction History

Renaissance Technologies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.26 - $0.55 $12,012 - $25,410	-46,200 Reduced 36.84%	79,201 $24,000
Q4 2022 Feb 13, 2023	SELL	$0.22 - $0.51 $29,326 - $67,983	-133,300 Reduced 51.53%	125,401 $63,000
Q3 2022 Nov 14, 2022	SELL	$0.67 - $1.26 $87,120 - $163,839	-130,031 Reduced 33.45%	258,701 $168,000
Q2 2022 Aug 12, 2022	BUY	$0.6 - $1.5 $28,939 - $72,348	48,232 Added 14.17%	388,732 $283,000
Q1 2022 May 13, 2022	BUY	$1.44 - $5.22 $243,936 - $884,268	169,400 Added 99.01%	340,500 $502,000
Q4 2021 Feb 11, 2022	BUY	$4.7 - $15.0 $752,940 - $2.4 Million	160,200 Added 1469.72%	171,100 $821,000
Q3 2021 Nov 12, 2021	BUY	$9.77 - $15.77 $106,493 - $171,893	10,900 New	10,900 $159,000

Ticker LABP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,254,900
Description
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of u...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.